MAVENIR
27.5.2021 15:02:13 CEST | Business Wire | Press release
Mavenir, the Network Software Provider building the future of networks with cloud-native software that runs on any cloud and transforms the way the world connects, has announced support for deployments and integration of cloud-native telecom network functions with telco infrastructure solutions on Amazon Web Services, Inc. (AWS).
Mavenir’s collaboration with AWS allows Communications Service Providers (CSPs) to deploy Mavenir’s market leading 4G and 5G products and applications with AWS’s computing infrastructure, state of the art container deployment and management technologies, and big data analytics services. The solution is designed to scale and leverages the same tools and technologies offered by AWS to enterprise applications today. These tools are the backbone for visibility and automation for any AWS-based offering and generally referred to as Platform-as-a-Service (PaaS). This translates to offloading some of the telco application business to cloud functions, reducing complexity and putting service providers at par with organizations enjoying cost savings from cloud migrations without losing insight, performance, and control on their networks.
Another key element from this collaboration is the enablement of Private Networks and Edge deployments on AWS, powered by Mavenir’s Digital Enablement platform . With a digital app store for enterprise and various industry 4.0 applications such as IVA, AR/VR, IIoT and Robotics control, Mavenir’s Edge AI application suite is empowering an ecosystem of developers, service providers, partners, and enterprises to create and deploy applications in AWS to power digitalization and industry 4.0 with 5G.
This collaboration also lowers the network deployment time and cost for MNOs and enterprises equally fulfilling use cases of either adding 5G and edge capabilities to an existing network or a greenfield 4G/5G network launch leveraging public clouds.
“The collaboration with Mavenir and AWS allows us to build out our 5G network and messaging platforms in a true cloud-native manner, harnessing the speed and agility that the AWS cloud brings along with Mavenir’s expertise in deploying and operating cloud-native network functions," said Sidd Chenumolu, Vice President of Technology Development, DISH. “Together, we will enable our customers to take full advantage of the potential of 5G, reimagining wireless connectivity and giving our customers the ability to customize their network experience.”
“Working with AWS enables us to bring new customer-focused 5G use cases and 5G deployments to the market faster and with unique capabilities to realize true 5G potential,” said Bejoy Pankajakshan, Mavenir’s Chief Strategy Officer. “Mavenir’s solutions are designed to support full public cloud as well as hybrid cloud deployments.”
"We’re delighted to collaborate with Mavenir to offer voice and messaging solutions for core network and RAN customers along with AI/ML solutions for orchestration and observability,” said Amir Rao, General Manager Telco Solution Portfolio and Tech Alliances, AWS. “Together, we are providing true cloud native benefits to CSP customers, combining Mavenir’s expertise in the NFV market with the global scale of the AWS infrastructure to meet industry challenges of agility, scaling, slicing, and resiliency.”
Mavenir’s 4G and 5G deployments on AWS provides unique capabilities, including:
- Integration of Mavenir’s cloud-native Open RAN (vDU, vCU-CP, vCU-UP), Converged 4G/5G Packet Core, IMS, and Messaging with Amazon Elastic Kubernetes Service (Amazon EKS) anywhere supporting AWS Outposts.
- Use of AWS platform services and tools to deploy and manage cloud native network functions.
- Options for existing deployments to migrate Mavenir’s IMS core, voice, and messaging solutions to Amazon EKS and Amazon Elastic Compute Cloud (Amazon EC2) infrastructure.
- Mavenir’s Orchestration and Network Slicing solutions to manage hybrid cloud workloads running on AWS.
- Adoption of AWS for centrally managed telco workloads on far-edge, network edge and core simultaneously.
- Deployment of Mavenir’s standards compliant observability framework, RIC, NWDAF, AIOps and Analytics platform in AWS to collect the data from various AWS nodes in a centrally managed data lake and process the data using AI/ML for network wide insights and optimization.
- Integration of Mavenir’s telecom adaptation layer (Telco PaaS) as a common open source-based platform adaptation layer designed for telco specific workloads to support various carrier grade requirements on top of Amazon EKS and AWS PaaS functions.
About Mavenir:
Mavenir is building the future of networks and pioneering advanced technology, focusing on the vision of a single, software-based automated network that runs on any cloud. As the industry's only end-to-end, cloud-native network software provider, Mavenir is focused on transforming the way the world connects, accelerating software network transformation for 250+ Communications Service Providers in over 120 countries, which serve more than 50% of the world’s subscribers.
Visit: www.mavenir.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20210527005102/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Consortium Led by Axelspace Selected for Japan’s Space Strategy Fund Project “Technology to Enhance Capability of Next Generation Earth Observation Satellites”30.3.2026 01:35:00 CEST | Press release
~ Creating Climate Solutions and New Market Opportunities through Source-Specific CO2 Emission and Uptake Monitoring via Satellite Constellation and Aircraft ~ Axelspace Corporation, Meisei Electric Co., Ltd., ANA HOLDINGS INC., and JIJ Inc. are pleased to announce that their jointly proposed technology development project has been selected for Japan Aerospace Exploration Agency (JAXA)’s Space Strategy Fund under the theme “Technology to Enhance Capability of Next Generation Earth Observation Satellites.” This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260323044518/en/ Conceptual Diagram of the project. Under this Space Strategy Fund initiative, spectrometers will be newly developed and demonstrated in orbit. In the future, the project envisions the establishment of a satellite constellation capable of observations at different times of the day. Project Summary (Planned) Technology Development Theme: Technology to Enhance Cap
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom